European medicines agency grants orphan drug designation for crofelemer to napo eu, jaguar health's italian subsidiary, for short bowel syndrome

The recognition of orphan drug designation in europe for crofelemer for this rare disease is the first key milestone of napo eu under the company's exclusive license agreement with jaguar health san francisco, ca and milan, italy / accesswire / december 13, 2021 / jaguar health (nasdaq:jagx) and its majority owned italian subsidiary, napo eu s.p.a. (soon to be renamed napo therapeutics), today announced that the european commission has adopted the decision to grant orphan drug designation (odd) for crofelemer for the indication of short bowel syndrome (sbs) in the european union following review of the odd application napo eu submitted to the european medicines agency (ema) this past september.
JAGX Ratings Summary
JAGX Quant Ranking